Leadership Team
Our leadership team is up to the task. We have more than three decades of innovation that lead to the creation of ASO technology coupled with a deep commitment to patients. We understand the challenges translating observations into drugs represents. Most importantly, we understand that every day matters, every minute matters to our patients. It is with this sense of urgency and commitment to quality at every step in the process that we can and are making a difference, today.
Leadership
Founder, Chief Executive Officer and Chairman of the Board
Dr. Stanley Crooke is founder, chairman and chief executive officer of n-Lorem, a nonprofit foundation focused on providing treatments for patients with nano-rare disease patients (1 to 30 patients worldwide), which he initiated in January 2020.
Prior to n- Lorem, Dr. Crooke founded and was Chairman and Chief Executive Officer and Lead Scientist of Ionis Pharmaceuticals. During his tenure at Ionis, he led the scientific development of a new platform for drug discovery, antisense technology and the creation of one of the largest and more advanced development pipelines in the biotechnology industry, and commercialized several antisense drugs including, SPINRAZA® (nusinersen), TEGSEDI™ (inotersen) and others. Early in Dr. Crooke’s career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D (president) at SmithKline Beckman (now GSK). During his tenure at SKB, Dr. Crooke led the restructuring of R&D and the development of several drugs that were commercialized.
Dr. Crooke has also contemporaneously led a successful academic career becoming a full professor at Baylor College of Medicine and the University of Pennsylvania Medical School where he trained a number of Ph.D. students and won several teaching awards. Dr. Crooke has been an active scientist throughout his career as well.
Dr. Crooke has received a number of awards, most recently, the Indiana University School of Medicine Steven C. Beering Award, the Prix Galien Roy Vagelos Pro Bono Humanum Award, the American Chemical Society’s E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award and the 2019 Massry Prize.
Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine, where he currently serves on the Board of Advisors. In 2021, Dr. Crooke has been named Distinguished Alumnus of both Baylor College of Medicine’s Graduate and Medical schools and named one of the 20 of the most influential biopharma R&D executives by Endpoints News. He has published nearly 600 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.
Chief Operating Officer
Chief Medical Officer
Vice President, ASO Discovery and Development
Executive Director, Clinical Development
Dr. Laurence Mignon is the executive director of clinical development at n-Lorem Foundation. Laurence has more than 20 years of experience as a seasoned academic researcher and clinical developer with a passion for rare diseases. Most recently, Laurence worked at Ionis Pharmaceuticals both in the Translational Medicine group and the Neurology Franchise Clinical Development group. In those roles, she implemented a novel genomic study to better understand genotype-phenotype associations and disease pathways, initiated the first clinical study in myotonic dystrophy type 1 and was a key member of the clinical team that brought SPINRAZA® (nusinersen), a disease-modifying therapy for patients with spinal muscular atrophy, to the market. Prior to Ionis, Laurence worked at Orexigen Therapeutics on the development of an obesity medication and at the Neuroscience Education Institute developing Continuing Medical Education material aimed at deconstructing the mechanism of action of psychiatric medications for psychiatrists, primary care physicians, and registered nurses. Laurence’s broad and diverse experience allows her to be strategically creative in her approach to deal with uncharted challenges. Laurence received her PhD in Pharmacology and Experimental Therapeutics from Loyola University Chicago and was a researcher for 6 years in the Department of Neurology at UCLA in the laboratory of Marie-Françoise Chesselet, studying properties of muscle-derived stem cells and the role of the serotonin pathway in Parkinson’s disease.
Vice President, Finance
Virginia Sankey is the vice president of finance at n-Lorem Foundation. Virginia is a seasoned finance professional with over 25 years of experience in accounting and finance. Virginia has extensive domestic and international experience in corporate accounting, financial reporting, financial planning and analysis, and strategic planning in companies of various sizes and industries. Her broad background includes extensive experience in biotech with research and development and operations finance. Prior to n-Lorem, Virginia held executive financial roles at several biotechnology companies. Additionally, Virginia was with PricewaterhouseCoopers (“PwC”) from 1990- 2010, working with companies across various industries and stages of development. Virginia received her B.S. in Accounting from Fairfield University and is licensed as a Certified Public Accountant in the State of California.
Executive Director, Communications and Donor Relations
Senior Director, Operations
Kim Butler is the senior director of operations at n-Lorem Foundation. Kim is a broadly experienced administrative assistant who has been employed by Ionis Pharmaceuticals since 2014 . During her tenure with Ionis she has been promoted several times and has assumed substantial managerial responsibilities. Additionally, she is accountable for leading the training of all administrative personnel and leads the management of administrative activities for Ionis. Currently, Kim is the senior administrative assistant to the Chairman and CEO of n-Lorem and has played an instrumental role in the formation of the foundation.
Prior to joining Ionis, Ms. Butler served in senior administrative positions in several organizations and has help found and participated in a number of charitable efforts. She is active in a wide range of civic service groups such as the American Legion and a frequent volunteer committed to serving the needy empathetically.
Director, Clinical Operations and Project Management
Megan Knutsen is the director of clinical operations and project management at n-Lorem Foundation. Megan brings a unique background of more than 20 years of experience as a clinical project manager, epidemiologist, and molecular biologist across pharma, biotech, CROs, and academia with a specific focus on rare diseases, oncology, and gene therapy. It is this combination of experience that drives Megan’s passion for a role at the intersection of science and translational clinical research.
Developing and managing the n-Lorem portfolio requires innovative thinking beyond what is done in traditional drug development. In her role at n-Lorem, Megan manages the portfolio by overseeing project management and operations of each patient program from application through treatment, ensuring efficiency, consistency, and organization at every step in between. Megan also manages several external collaborations of strategic importance to n-Lorem.
Megan received her Master of Science in Epidemiology with an emphasis in Public Health Genetics from University of Washington, holds a professional certificate in Clinical Trial Design and Management from the University of California, San Diego, and is a licensed Clinical Genetic Molecular Biologist Scientist by the state of California.
Senior Director, Discovery and Research
Board of Directors
Executive Vice President, Chief Scientific Officer of Ionis Pharmaceuticals
Dr. Bennett is the executive vice president and chief scientific officer at Ionis Pharmaceuticals and one of the founding members of the company. He is responsible for continuing to advance Ionis’ technology and expanding the company’s drug discovery platform. Dr. Bennett is also the franchise leader for gene-editing programs at Ionis. He has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry.
Dr. Bennett has been recognized for his research with numerous awards. He is a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research, the 2021 Gabbay Award and the 2019 Breakthrough Prize in Life Sciences for his contributions to the discovery and development of SPINRAZA® (nusinersen), and the inaugural Healy Center International Prize for Innovation in amyotrophic lateral sclerosis (ALS). Dr. Bennett also received the 2018 Hereditary Disease Foundation’s (HDF) Leslie Gehry Brenner Prize for Innovation in Science for his leadership and continued commitment to developing antisense therapies for Huntington’s disease (HD).
Dr. Bennett has published more than 230 papers in the field of antisense research and development, and he is an inventor on more than 175 issued patents.
Prior to joining Ionis, Dr. Bennett was associate senior investigator in the Department of Molecular Pharmacology at SmithKline and French Laboratories (currently, GlaxoSmithKline).
He received his Ph.D. in Pharmacology from Baylor College of Medicine, Houston, Texas and his B.S. degree in Pharmacy from the University of New Mexico, Albuquerque, New Mexico. He performed his postdoctoral research in the Department of Molecular Pharmacology at SmithKline and French Laboratories.
Dr. Bennett serves on the Advisory Board for the Hereditary Disease Foundation and SAB for the McLaughlin Institute.
Chairman of Investment Banking, Barclays
Founder of n-Lorem
Killam Professor of Medical Genetics at University of British Columbia
Dr. Michael Hayden is a Killam Professor at the University of British Columbia and the director of the Translational Laboratory in Genetic Medicine at the National University of Singapore and the Agency for Science, Technology and Research (A*STAR). From 2012 to 2017, he served as president of Global R&D and chief scientific officer at Teva Pharmaceutical Industries Ltd. Dr. Hayden built and transformed research and development at Teva to become a highly productive research engine and was instrumental in the approval of approximately 30 new products.
Dr. Hayden has founded three biotechnology companies and has been the recipient of numerous prestigious honors and awards including being inducted into the Canadian Medical Hall of Fame, receiving the July 2012 Diamond Jubilee Medal, on behalf of HRH Queen Elisabeth II and the Margolese National Brain Disorder Prize, awarded to Canadians who have made outstanding contributions to the treatment, amelioration, or cure of brain diseases. He’s also received the Canada Gairdner Wightman award for his outstanding leadership in medicine and medical science as a physician-scientist. Dr. Hayden was awarded the Order of Canada, the Order of British Columbia, named Canada’s Health Researcher of the Year by Canadian Institutes of Health Research, and has received the Prix Galien for his contribution to Canadian pharmaceutical research. Most recently, Dr. Hayden was named one of the 50 Canadians born in the 20th century who have changed the world.
Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory
Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery, especially for rare and ultra-rare diseases; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel reimbursement models for creating a robust gene and cell therapy ecosystem. He is a co-founder of BridgeBio Pharma, QLS Advisors, Quantile Health, and Uncommon Cures; a director of AbCellera, Atomwise, BridgeBio, Uncommon Cures, and Vesalius; and a member of the advisory board to the American Cancer Society’s BrightEdge Impact Fund. Lo received his B.A. in economics from Yale University and his A.M. and Ph.D. in economics from Harvard University.
Senior Physician & Head of the Department of Medicine at Brigham & Women’s Hospital, Harvard Medical School, and Executive Committee Member of UDN
Dr. Joseph Loscalzo is Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, chairman of the Department of Medicine, and physician-in-chief at Brigham and Women’s Hospital. Dr. Loscalzo received his A.B. degree, summa cum laude, his Ph.D. in biochemistry, and his M.D. from the University of Pennsylvania. His clinical training was completed at Brigham and Women’s Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine.
Post-training, Dr. Loscalzo joined the Harvard faculty and staff at Brigham and Women’s Hospital in 1984. He rose to the rank of associate professor of Medicine, Chief of Cardiology at the West Roxbury Veterans Administration Medical Center, and director of the Center for Research in Thrombolysis at Brigham and Women’s Hospital. He joined the faculty of Boston University in 1994, first as Chief of Cardiology and, in 1997, Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. He returned to Harvard and Brigham and Women’s Hospital in 2005. He currently serves on the board of directors of Leap Therapeutics, Inc., a publicly held biopharmaceutical company, and is an executive committee member of the UDN.
Chief Executive Officer and Co-founder of Sequel MedTech LLC
Alan Lotvin, MD, is the Chief Executive Officer and Co-founder of Sequel MedTech LLC, a company bringing the next-generation of drug delivery technology to millions of people living with chronic disease.
Previously Alan served as Executive Vice President CVS Health and President CVS Caremark. In this role, Dr. Lotvin led all CVS Caremark to be the nation’s leading pharmacy benefit management (PBM) business — leading all sales, account management and operations. Dr. Lotvin also served as executive vice president and chief transformation officer of CVS Health, and before that executive vice president of CVS Specialty, the specialty pharmacy of CVS Health.
Before joining CVS Health in 2012, Lotvin was president and chief executive officer of ICORE Healthcare, a Magellan Health Services company. Dr. Lotvin has held multiple roles at Medco Health Solutions, including president of Medco Specialty Pharmacy Services and senior vice president of Manufacturer Contracting.
Dr. Lotvin holds US Patent #6269819 Method and Apparatus for Circulatory Valve Repair. He is co-author of the book Live Better, Live Longer.
Lotvin began his career as a practicing cardiologist in New Jersey. He holds a master’s degree in Medical Informatics from Columbia University and a Medical Degree from the State University of New York Health Sciences Center in Brooklyn.
Executive Director of The Wolverine Foundation
Board of Directors
Director Hyman, Phelps & McNamara, P.C.
Frank J. Sasinowski is director of Hyman, Phelps & McNamara, P.C., and an Adjunct Professor of Neurology at the University of Rochester School of Medicine. He brings more than 20 years of board experience at prestigious institutions, including the Alliance for Regenerative Medicine (ARM) Foundation for Cell and Gene Medicine, National Organization for Rare Disorders (NORD), EveryLife Foundation for Rare Diseases, the IndoUSrare patient organization, the United States Pharmacopeia (USP) and various notable biotechnology companies.
After joining the U.S. Food and Drug Administration (FDA) in 1983 as regulatory counsel in the Center for Drugs and Biologics, Sasinowski became a key player in the implementation of foundational legislation such as the 1983 Orphan Drug Act and 1984 Hatch-Waxman Act. He worked with the FDA for nearly half a decade before leaving his position as the Deputy Director of health policy in the Commissioner’s office and joining Hyman, Phelps & McNamara, P.C. Sasinowski used his experience working in the drug regulatory process to help secure FDA approval for hundreds of new drugs, including more than 100 new molecular entities – often for serious and rare diseases.
Sasinowski has been widely recognized for his expertise by the life sciences sector, patient advocacy organizations and notable world leaders, including former President Barack Obama, who recognized his contributions to the President’s Council of Advisors on Science and Technology (PCAST) report in 2012. He is the recipient of numerous awards, including NORD’s first-ever Lifetime Achievement Award, as well as the FDA’s Award of Merit and NORD’s Humanitarian Award, where he was honored for his work benefiting the rare disease community. Most recently, Sasinowski received Pope Francis’ 2021 Pontifical Hero Award for Inspiration as recognition for his leadership, advocacy and unwavering dedication to patients living with rare disease.
Claire Tow Associate Professor of Motor Neuron Disorders and Director of the Eleanor and Lou Gehrig ALS Center at Columbia University
Dr. Neil Shneider serves as the Claire Tow Associate Professor of Motor Neuron Disorders and the Director of the Eleanor and Lou Gehrig ALS Center at Columbia University. He is an investigator in the Center for Motor Neuron Biology and Disease where his lab focuses on the study of models and mechanisms of ALS and the discovery and development of novel therapeutics for ALS and related disorders. Dr. Shneider worked with Ionis Pharmaceuticals to develop ION363 (Jacifusen), an anti-sense oligonucleotide (ASO) for ALS patients with rare mutations in the FUsed in Sarcoma (FUS) gene. Dr. Shneider is a graduate of Harvard College and earned his M.D. and Ph.D. degrees at the Columbia University College of Physicians and Surgeons.
In partnership with n-Lorem and Columbia University, Dr. Shneider founded Silence ALS, an initiative to develop ASOs for ALS patients with nano-rare, pathogenic mutations in ALS genes. Dr. Shneider was co-chair of the Translating Fundamental Research into Potential ALS Therapies Working Group for the NIH ALS Strategic Planning Workshop.
Founder and CEO of J. Wood Capital Advisors
University of California San Diego Professor, Dept. of Cellular and Molecular Medicine
Committees
Every patient deserves expert advice about treatment. At n-Lorem, we have a number of committees that provide expert advice across all key steps.
The Access to Treatment Committee reviews applications submitted by research physicians to treat genetically confirmed nano-rare disease patients.
The Study Treatment and Assessment Review Committee provides n-Lorem and the patient’s physicians guidance on the development of treatment goals and clinical outcome assessments for n-Lorem’s diverse patient population.
The DSMB (Data Safety Monitoring Board) provides unbiased safety oversight through interim monitoring of accumulating data from all of the investigator-initiated studies evaluating n-Lorem ASO medicines.
We cannot do
this alone
Together we are changing the world—
one patient at a time
We hope that you join us on this journey to discover, develop and provide individualized antisense medicines for free for life for nano-rare patients. The ultimate personalized medicine approach – for free, for life.
We need your support
